Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382811537> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4382811537 endingPage "S165" @default.
- W4382811537 startingPage "S164" @default.
- W4382811537 abstract "Currently, there are no reliable biomarkers to predict the effectiveness of FOLFIRINOX/FOLFOX regimens. Predictive tests that assist clinicians in choosing the most appropriate first-line chemotherapy regimen are needed. In 2022, we developed a blood-based RNA signature, the GemciTest, which predicts the response to gemcitabine-based first-line treatment in patients with PDAC. The objective of this study was to evaluate the effectiveness of a complementary blood-based RNA signature (F/FX) to predict the response to FOLFIRINOX/FOLFOX regimens in advanced pancreatic adenocarcinoma. Clinical validation was conducted through a discovery and a validation phase on 164 previously untreated advanced PDAC patients (at baseline) (mean age of 68.7 years; 37-88) who received either a gemcitabine- or fluoropyrimidine-based regimen (Id.: NCT03599154 and NCT02818829). The F/FX test measures the expression levels of ten genes using real-time PCR process (MCEMP1, S100A12, MMP9, RACK1, DSC2, LYN, LPP, ARL4C, ALDOA and AC007877.1). Among FOLFIRINOX/FOLFOX treated patients (n=90), those with a positive F/FX (31.1%) had a significantly longer progression-free survival (PFS) (14.3 vs. 3.5 months; HR=0.21 (95% confidence interval CI: 0.12–0.35); p=5.56e-09) and median overall survival (OS) (23 vs. 7.7 months; HR=0.22 (95% CI: 0.13–0.36); p=3.16e-09). The Pearson correlation coefficient between OS and PFS was 0.73 (95% CI: 0.62-0.81; p=2,2E-16). On the contrary, gem-based treated patients (n=74) showed no significant difference in PFS (11.3 vs. 5.8 months; HR=0.68 (95% CI: 0.24–1.91); p=0.48) and OS (13.6 vs. 7.3 months; HR=0.7 (95% CI: 0.25–1.95); p=0.5) between the patients with a positive F/FX versus the patients with a negative F/FX. The F/FX demonstrates the potential of a blood-based RNA signature as a minimally-invasive alternative to improve patient survival and implement personalized therapy in PDAC for patients treated with a FOLFIRINOX/FOLFOX regimen as first-line treatment. While these data show promise, they should be confirmed in a prospective trial, distinguishing patients with non resectable locally advanced and those with metastatic tumors." @default.
- W4382811537 created "2023-07-02" @default.
- W4382811537 creator A5002063921 @default.
- W4382811537 creator A5005401492 @default.
- W4382811537 creator A5008275027 @default.
- W4382811537 creator A5020083980 @default.
- W4382811537 creator A5020133150 @default.
- W4382811537 creator A5032193447 @default.
- W4382811537 creator A5043463827 @default.
- W4382811537 creator A5043962640 @default.
- W4382811537 creator A5052299853 @default.
- W4382811537 creator A5058660922 @default.
- W4382811537 creator A5060346666 @default.
- W4382811537 creator A5060437148 @default.
- W4382811537 creator A5061710022 @default.
- W4382811537 creator A5064519018 @default.
- W4382811537 creator A5065614520 @default.
- W4382811537 creator A5073954292 @default.
- W4382811537 creator A5075897519 @default.
- W4382811537 creator A5078065507 @default.
- W4382811537 creator A5081144678 @default.
- W4382811537 creator A5087509645 @default.
- W4382811537 date "2023-06-01" @default.
- W4382811537 modified "2023-10-16" @default.
- W4382811537 title "SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer" @default.
- W4382811537 doi "https://doi.org/10.1016/j.annonc.2023.04.480" @default.
- W4382811537 hasPublicationYear "2023" @default.
- W4382811537 type Work @default.
- W4382811537 citedByCount "0" @default.
- W4382811537 crossrefType "journal-article" @default.
- W4382811537 hasAuthorship W4382811537A5002063921 @default.
- W4382811537 hasAuthorship W4382811537A5005401492 @default.
- W4382811537 hasAuthorship W4382811537A5008275027 @default.
- W4382811537 hasAuthorship W4382811537A5020083980 @default.
- W4382811537 hasAuthorship W4382811537A5020133150 @default.
- W4382811537 hasAuthorship W4382811537A5032193447 @default.
- W4382811537 hasAuthorship W4382811537A5043463827 @default.
- W4382811537 hasAuthorship W4382811537A5043962640 @default.
- W4382811537 hasAuthorship W4382811537A5052299853 @default.
- W4382811537 hasAuthorship W4382811537A5058660922 @default.
- W4382811537 hasAuthorship W4382811537A5060346666 @default.
- W4382811537 hasAuthorship W4382811537A5060437148 @default.
- W4382811537 hasAuthorship W4382811537A5061710022 @default.
- W4382811537 hasAuthorship W4382811537A5064519018 @default.
- W4382811537 hasAuthorship W4382811537A5065614520 @default.
- W4382811537 hasAuthorship W4382811537A5073954292 @default.
- W4382811537 hasAuthorship W4382811537A5075897519 @default.
- W4382811537 hasAuthorship W4382811537A5078065507 @default.
- W4382811537 hasAuthorship W4382811537A5081144678 @default.
- W4382811537 hasAuthorship W4382811537A5087509645 @default.
- W4382811537 hasConcept C121608353 @default.
- W4382811537 hasConcept C126322002 @default.
- W4382811537 hasConcept C143998085 @default.
- W4382811537 hasConcept C2776694085 @default.
- W4382811537 hasConcept C2777148230 @default.
- W4382811537 hasConcept C2778260052 @default.
- W4382811537 hasConcept C2780210213 @default.
- W4382811537 hasConcept C2780258809 @default.
- W4382811537 hasConcept C2780962732 @default.
- W4382811537 hasConcept C2781413609 @default.
- W4382811537 hasConcept C44249647 @default.
- W4382811537 hasConcept C526805850 @default.
- W4382811537 hasConcept C71924100 @default.
- W4382811537 hasConceptScore W4382811537C121608353 @default.
- W4382811537 hasConceptScore W4382811537C126322002 @default.
- W4382811537 hasConceptScore W4382811537C143998085 @default.
- W4382811537 hasConceptScore W4382811537C2776694085 @default.
- W4382811537 hasConceptScore W4382811537C2777148230 @default.
- W4382811537 hasConceptScore W4382811537C2778260052 @default.
- W4382811537 hasConceptScore W4382811537C2780210213 @default.
- W4382811537 hasConceptScore W4382811537C2780258809 @default.
- W4382811537 hasConceptScore W4382811537C2780962732 @default.
- W4382811537 hasConceptScore W4382811537C2781413609 @default.
- W4382811537 hasConceptScore W4382811537C44249647 @default.
- W4382811537 hasConceptScore W4382811537C526805850 @default.
- W4382811537 hasConceptScore W4382811537C71924100 @default.
- W4382811537 hasLocation W43828115371 @default.
- W4382811537 hasOpenAccess W4382811537 @default.
- W4382811537 hasPrimaryLocation W43828115371 @default.
- W4382811537 hasRelatedWork W1523425138 @default.
- W4382811537 hasRelatedWork W2012954058 @default.
- W4382811537 hasRelatedWork W2138640290 @default.
- W4382811537 hasRelatedWork W2410090482 @default.
- W4382811537 hasRelatedWork W2599910524 @default.
- W4382811537 hasRelatedWork W2910998150 @default.
- W4382811537 hasRelatedWork W2966671351 @default.
- W4382811537 hasRelatedWork W2999008429 @default.
- W4382811537 hasRelatedWork W3184807956 @default.
- W4382811537 hasRelatedWork W4286295729 @default.
- W4382811537 hasVolume "34" @default.
- W4382811537 isParatext "false" @default.
- W4382811537 isRetracted "false" @default.
- W4382811537 workType "article" @default.